gene editing

Strain-specific outcomes of cytosine-base editing in Streptomyces

It is observed that in certain Streptomyces spp.

CRISPR therapy for dyslipidemia.

The potential for gene editing and epigenetic therapy for the management of dyslipidemia appears to be well tolerated, and a number of agents with the potential for robust and durable changes to atherosclerotic lipid and lipoprotein risk factors are developed.

Gene-editing technologies and gene delivery modalities for neurodegenerative disorders: Current advances and challenges

Establishment of an efficient in-vitro regeneration system from leaves of Phalaenopsis hybrida cv. ‘Big Chili’

GENESIS-SHIELD: an interpretable ensemble for anomaly detection in CRISPR genomic-workflow security

The rapid advancement of CRISPR-based gene editing has introduced digital-workflow security and integrity challenges: unauthorized modifications, temporal inconsistencies, and duplicated provenance records can compromise the auditability of editing logs. These are distinct from the biological risks of editing its...

CRISPR-Based Mediated Reactivation of Fetal Hemoglobin as a Therapeutic Strategy for Hemoglobinopathies: Evidence from Preclinical to Clinical Trials in Sickle Cell Disease and β-Thalassemia.

Overall, the available evidence suggests that CRISPR-based HbF reactivation is a promising therapeutic approach for β-hemoglobinopathies, although long-term efficacy and safety data remain necessary.

Gene therapy in amyotrophic lateral sclerosis (ALS)

Gene therapy in limb-girdle muscular dystrophy (LGMD)

Graft Biology in the CRISPR Era: From Tissue Fusion to Genome Compatibility

This review synthesizes current advances in embryonic grafting, discusses the molecular basis of graft compatibility and reproductive stability, and highlights key challenges and future research directions for integrating developmental biology with genome editing to improve graft success across wider taxonomic boundari...

Gene therapy in Alzheimer’s disease (AD)

Gene therapy in Huntington’s disease (HD)

Gene therapy in Duchenne muscular dystrophy (DMD)